Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.
News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.
Celyad Oncology announced ongoing enrollment in its Phase 1 dose-escalation trial for CYAD-211, targeting relapsed/refractory multiple myeloma. The FDA lifted the hold on CYAD-101 for metastatic colorectal cancer. The company reported a net loss of €14.1 million for H1 2022, an improvement from €14.9 million in H1 2021. Cash reserves stand at €14.4 million. Research and development expenses rose to €10.5 million due to increased IP costs. Celyad aims to enhance partnerships leveraging its extensive CAR T technology IP portfolio.
Celyad Oncology (CYAD) announced the FDA has lifted the clinical hold on its CYAD-101-002 (KEYNOTE-B79) Phase 1b trial, enabling the continuation of its investigation into allogeneic NKG2D CAR T cell therapy combined with KEYTRUDA for refractory metastatic colorectal cancer. The trial had been paused due to safety concerns following reports of fatalities. Celyad remains optimistic about the potential of CYAD-101 and its proprietary TIM technology.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced plans to report its first half 2022 financial and operating results on August 5, 2022. Following this release, management will host a conference call at 2 p.m. CEST to discuss the results and updates on recent progress and milestones.
The company is focused on CAR T therapies for cancer and has a pipeline of candidates for treating hematological malignancies and solid tumors. Detailed insights on its financial condition and ongoing trials, including the CYAD-101-002 trial, will be provided during the call.
Celyad Oncology SA (NASDAQ:CYAD) announced the appointment of Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Windels has been on the board since May 2018 and has extensive experience in the life sciences sector. She replaces Michel Lussier, who becomes the Interim Chief Executive Officer following the resignation of Filippo Petti. Petti will assist during the transition until July 31, 2022. The company's strategy focuses on developing innovative CAR T therapies for cancer.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that as of May 25, 2022, 350 registered shares will benefit from double voting rights. This change increases the total number of voting rights to 24,962,331. The company disclosed this in compliance with Belgian regulations regarding major shareholdings. Key figures include a total share capital of €78,584,224.33, with 20,225,581 shares having single voting rights and 2,368,375 shares having double voting rights.
Celyad Oncology SA (Brussels:CYAD) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company will present virtually, with on-demand access starting at 7:00 a.m. EST on May 24, 2022. Celyad Oncology focuses on developing CAR T therapies for cancer, including both allogeneic and autologous candidates targeting hematological malignancies and solid tumors. The company, founded in 2007, received funding from the Walloon Region of Belgium to support its programs.
The financial update from Celyad Oncology (CYAD) highlights a cash position of €20.5 million ($22.9 million) and a net cash burn of €9.5 million ($10.6 million) for Q1 2022. The Phase 1 IMMUNICY-1 trial for CYAD-211 continues to enroll patients to evaluate its effectiveness against relapsed/refractory multiple myeloma. However, the CYAD-101-002 Phase 1b trial remains on clinical hold due to safety concerns, following reported fatalities. The company plans to release additional data on CYAD-211 in H2 2022 and expects its cash reserves to last until mid-2023.
Summary not available.
Celyad Oncology SA (NASDAQ: CYAD) provided an update on its business and financial results for Q1 2022. The Phase 1 IMMUNICY-1 trial for the allogeneic CAR T candidate CYAD-211 for relapsed/refractory multiple myeloma (MM) is ongoing, with additional data expected in H2 2022. However, the CYAD-101-002 Phase 1b trial remains on clinical hold after two fatalities were reported. As of March 31, 2022, the company had €20.6 million in cash, with a net cash burn of €9.4 million during the quarter, sufficient to fund operations until mid-2023.
Celyad Oncology (CYAD) reported its 2021 results, showing a net loss of €26.5 million or €1.70 per share, a significant increase from €17.2 million or €1.23 per share in 2020. The company had cash and equivalents of €30 million as of Dec 31, 2021, expected to fund operations until mid-2023. Clinical updates included encouraging results from the Phase 1 IMMUNICY-1 trial of CYAD-211 for relapsed/refractory multiple myeloma, while the CYAD-101 Phase 1b trial is on clinical hold. The firm anticipates upcoming data releases and IND submissions in 2022.